Paper · 2026 · Open access

Pharmacogenomics and Personalized Medicine

Kiran Rayate*, Rahul Khaire, Namrata Godhari, Vaishnavi Devhad, Sharavari Mhaske

Zenodo (CERN European Organization for Nuclear Research) · Published 11 September 2026 · DOI 10.5281/zenodo.22714144

Open full textCite this paper

In brief

“Pharmacogenomics and Personalized Medicine” is a 2026 paper by Kiran Rayate*, Rahul Khaire, Namrata Godhari, Vaishnavi Devhad, Sharavari Mhaske, published in Zenodo (CERN European Organization for Nuclear Research). OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Zenodo (CERN European Organization for Nuclear Research).

Citations
0
Authors
1

Abstract

Pharmacogenomics (PGx) represents a paradigm shift from the traditional "one-sizefits-all" approach to medicine toward personalized, genetically-informed therapeutic strategies. This review comprehensively examines the scientific foundations, clinical applications, implementation challenges, and future directions of pharmacogenomics in modern healthcare. PGx studies how an individual's genetic makeup influences drug response, including efficacy, toxicity, and optimal dosing. Key pharmacogenetic markers include polymorphisms in cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP2C9), drug transporter genes (SLCO1B1), and genes involved in drug targets and immune responses (HLA-B, VKORC1, TPMT, DPYD). Clinical applications are particularly advanced in oncology, cardiology, psychiatry, and infectious diseases, where genetic testing guides the use of drugs such as warfarin, clopidogrel, codeine, abacavir, carbamazepine, trastuzumab, and fluoropyrimidines. Despite demonstrated benefits in optimizing therapeutic outcomes and reducing adverse drug reactions (ADRs), widespread adoption faces significant barriers including limited clinician awareness, high testing costs, insufficient regulatory frameworks, ethical concerns, and infrastructural constraints. Emerging technologies such as next-generation sequencing (NGS), electronic health record (EHR) integration, artificial intelligence (AI)-driven clinical decision support, and multi-omics integration are expected to accelerate clinical implementation. This review highlights current evidence, practical considerations for pharmacy practitioners, and the systemic changes needed to fully realize the potential of pharmacogenomics in routine clinical practice, ultimately advancing toward safer, more effective, and truly personalized medicine.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Mhaske, K. R. R. K. N. G. V. D. S. (2026). Pharmacogenomics and Personalized Medicine. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.22714144

MLA 9

Mhaske, Kiran Rayate*, Rahul Khaire, Namrata Godhari, Vaishnavi Devhad, Sharavari. “Pharmacogenomics and Personalized Medicine.” Zenodo (CERN European Organization for Nuclear Research), 2026. https://doi.org/10.5281/zenodo.22714144.

Chicago

Mhaske, Kiran Rayate*, Rahul Khaire, Namrata Godhari, Vaishnavi Devhad, Sharavari. 2026. “Pharmacogenomics and Personalized Medicine.” Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.22714144.

Harvard

Mhaske, K. R. R. K. N. G. V. D. S. (2026) ‘Pharmacogenomics and Personalized Medicine’, Zenodo (CERN European Organization for Nuclear Research). doi:10.5281/zenodo.22714144.

IEEE

K. R. R. K. N. G. V. D. S. Mhaske, “Pharmacogenomics and Personalized Medicine,” Zenodo (CERN European Organization for Nuclear Research), 2026, doi: 10.5281/zenodo.22714144.

BibTeX

@article{mhaske2026pharmacogenomics,
  title     = {{Pharmacogenomics and Personalized Medicine}},
  author    = {Mhaske, Kiran Rayate*, Rahul Khaire, Namrata Godhari, Vaishnavi Devhad, Sharavari},
  journal   = {Zenodo (CERN European Organization for Nuclear Research)},
  year      = {2026},
  doi       = {10.5281/zenodo.22714144},
  url       = {https://doi.org/10.5281/zenodo.22714144}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenomics
  • personalized medicine
  • pharmacogenetic markers
  • cytochrome P450 polymorphisms
  • drug transporter genes
  • HLA-B
  • adverse drug reactions
  • pharmacogenetic testing

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Mhaske, K. R. R. K. N. G. V. D. S. (2026). Pharmacogenomics and Personalized Medicine. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.22714144

How many times has this paper been cited?

0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Zenodo (CERN European Organization for Nuclear Research): sign in and open the full text from this page.

Who wrote this paper?

Kiran Rayate*, Rahul Khaire, Namrata Godhari, Vaishnavi Devhad, Sharavari Mhaske.

What is the DOI of this paper?

10.5281/zenodo.22714144, permanently at https://doi.org/10.5281/zenodo.22714144. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.